The effect and safety of new chemotherapy regimen for advanced gallbladder carcinoma: an open multicenter randomized controled trial
10.3760/cma.j.issn.1007-8118.2010.11.003
- VernacularTitle:晚期胆囊癌化疗新方案有效性、安全性的随机、对照、开放、多中心临床研究
- Author:
Zhiwei QUAN
;
Zhaohui TANG
;
Pengyuan ZHUANG
- Publication Type:Journal Article
- Keywords:
Advanced gallbladder carcinoma;
Chemotherapy regimen;
Somatostatin
- From:
Chinese Journal of Hepatobiliary Surgery
2010;16(11):809-811
- CountryChina
- Language:Chinese
-
Abstract:
Comprehensive therapy is the leading method to improve the overall survival for patients with advanced gallbladder cancer, especially the study of new chemotherapy regimen are on demand.From 2010 to 2011, a phase Ⅲ study of new chemotherapy regimen in the treatment of advanced gallbladder carcinoma would be undertaken nationwide to assess the clinical outcome and safety, in 31 clinical centers led by the department of General Surgery of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and a total of 260 patients would be accrued for this study.Chemotherapy consists of 2 regimes, conventional regime(cisplatin, epirubicin, and 5-fluorouracil, leucovorin)and new regime(conventional regime plus somatostatin).At present, the study has been approved by Clinical Trial Registration Platform of National Institutes of Health in U.S.A., and more than 30 patients are rolling in the study.The clinical trial could provide the high-quality evidence of EBM(evdence based medicine)for the chemotherapy of advanced gallbladder caner, and it will be one of the important components in the large-scale clinical study of chemotherapy for the advanced gallbladder cancer in China and worldwide.
